- Home
- CSTL vs TYRA Comparison
CSTL vs TYRA Comparison
Compare CSTL & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- TYRA
- Stock Information
- Founded
- CSTL 2007
- TYRA 2018
- Country
- CSTL United States
- TYRA United States
- Employees
- CSTL N/A
- TYRA N/A
- Industry
- CSTL Medical Specialities
- TYRA Biotechnology: Pharmaceutical Preparations
- Sector
- CSTL Health Care
- TYRA Health Care
- Exchange
- CSTL Nasdaq
- TYRA Nasdaq
- Market Cap
- CSTL 555.8M
- TYRA 571.9M
- IPO Year
- CSTL 2019
- TYRA 2021
- Fundamental
- Price
- CSTL $24.21
- TYRA $12.53
- Analyst Decision
- CSTL Strong Buy
- TYRA Strong Buy
- Analyst Count
- CSTL 6
- TYRA 7
- Target Price
- CSTL $37.67
- TYRA $30.43
- AVG Volume (30 Days)
- CSTL 712.7K
- TYRA 217.4K
- Earning Date
- CSTL 08-04-2025
- TYRA 08-14-2025
- Dividend Yield
- CSTL N/A
- TYRA N/A
- EPS Growth
- CSTL N/A
- TYRA N/A
- EPS
- CSTL N/A
- TYRA N/A
- Revenue
- CSTL $346,269,000.00
- TYRA N/A
- Revenue This Year
- CSTL N/A
- TYRA N/A
- Revenue Next Year
- CSTL N/A
- TYRA N/A
- P/E Ratio
- CSTL N/A
- TYRA N/A
- Revenue Growth
- CSTL 20.40
- TYRA N/A
- 52 Week Low
- CSTL $14.59
- TYRA $6.42
- 52 Week High
- CSTL $35.84
- TYRA $29.60
- Technical
- Relative Strength Index (RSI)
- CSTL 76.51
- TYRA 63.17
- Support Level
- CSTL $20.35
- TYRA $12.34
- Resistance Level
- CSTL $20.80
- TYRA $13.16
- Average True Range (ATR)
- CSTL 0.95
- TYRA 0.73
- MACD
- CSTL 0.45
- TYRA 0.17
- Stochastic Oscillator
- CSTL 96.67
- TYRA 80.24
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.